FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon Blood creatinine increased, pollakiuria, proteinuria
Croatian: Manje često Povišeni kreatinin u krvi, polakizurija, proteinurija
English: The MAH shall ensure that the educational programme implemented for the authorised indications of treatment of osteoporosis in post-menopausal women and in men at increased risk of fracture, including those with a recent low-trauma hip fracture, and treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture is updated.
Croatian: Nositelj odobrenja mora osigurati ažuriranje programa izobrazbe koji se provodi za odobrene indikacije liječenja osteoporoze u postmenopauzalnih žena te u muškaraca s povećanim rizikom od prijeloma, uključujući one s nedavnim prijelomom kuka nakon manje traume, te liječenja osteoporoze povezane s dugotrajnom sistemskom terapijom glukokortikoidima u postmenopauzalnih žena i u muškaraca s povećanim rizikom od prijeloma.
English: Treatment with Aclasta resulted in an increase in BMD of 5.4% at the total hip and 4.3% at the femoral neck over 24 months as compared to placebo.
Croatian: Liječenje Aclastom rezultiralo je povećanjem BMD-a od 5,4% cijelog kuka i 4,3% vrata bedrene kosti više od 24 mjeseca u usporedbi s placebom.
English: Patients who were classified as responders at the end of the 6 month core study were eligible to enter an extended follow-up period.
Croatian: Bolesnici koji su na kraju šestomjesečnog osnovnog kliničkog ispitivanja bili klasificirani kao osobe koje pokazuju terapijski odgovor, bili su prikladni za uključenje u produljeni period praćenja.
English: B-CTx was significantly reduced by 61% below baseline levels at 12 months and was sustained at 55% below baseline levels at 36 months.
Croatian: B-CTx je bio značajno smanjen za 61% ispod početnih razina u 12. mjesecu, što je održano na 55% ispod početnih razina u 36. mjesecu.
English: Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
Croatian: Liječenje osteoporoze povezane s dugotrajnom sistemskom terapijom glukokortikoidima
English: P1NP was significantly reduced by 61% below baseline levels at 12 months and was sustained at 52% below baseline levels at 36 months.
Croatian: P1NP je bio značajno smanjen za 61% ispod početnih razina u 12. mjesecu, što je održano na 52% ispod početnih razina u 36. mjesecu.
English: Headache, dizziness, sickness, vomiting, diarrhoea, pain in the muscles, pain in the bones and/or joints, pain in the back, arms or legs, flu-like symptoms (e.g. tiredness, chills, joint and muscle pain), chills, feeling of tiredness and lack of interest, weakness, pain, feeling unwell, swelling and/or pain at the infusion site.
Croatian: Glavobolja, omaglica, mučnina, povraćanje, proljev, bol u mišićima, bol u kostima i/ili zglobovima, bol u leđima, rukama ili nogama, simptomi nalik gripi (npr. umor, zimica, bol zglobova ili mišića), zimica, osjećaj umora i gubitak interesa, slabost, bol, loše osjećanje, oticanje i/ili bol na mjestu infuzije.
English: All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, non-healing of sores or discharge during treatment with zoledronic acid.
Croatian: Tijekom liječenja zoledronatnom kiselinom sve bolesnike se mora poticati da održavaju dobru oralnu higijenu, redovito odlaze na stomatološke kontrole i odmah prijave bilo koji oralni simptom kao što je pomičnost zuba, bol ili oticanje, ranice koje ne cijele ili iscjedak.
English: Multipack
Croatian: Višestruko pakiranje
English: Zoledronic acid is eliminated by renal excretion.
Croatian: Zoledronatna kiselina se eliminira izlučivanjem bubrezima.
English: Aclasta (N=1,065) event rate
Croatian: Aclasta (n=1065) stopa događaja
English: Patients treated with Aclasta should be given the package leaflet and the patient reminder card.
Croatian: Bolesnicima koji se liječe Aclastom potrebno je dati uputu o lijeku i karticu s podsjetnikom za bolesnika.
English: - Poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, invasive dental procedures, e.g. tooth extractions.
Croatian: - Lošu oralnu higijenu, periodontalnu bolest, zubnu protezu koja loše prijanja, bolest zuba u anamnezi, invazivne zahvate na zubima, npr. ekstarkcija zuba.
English: Myalgia, arthralgia, bone pain, back pain, pain in extremity
Croatian: Mialgija, artralgija, bol u kositma, bol u leđima, bol u ekstremitetima
English: The increases in BMD were significantly greater in the Aclasta-treated group at the lumbar spine and femoral neck at 12 months compared to risedronate (all p<0.03).
Croatian: Povećanja BMD-a lumbalne kralježnice i vrata bedrene kosti bila su značajno veća u skupini liječenih Aclastom u 12. mjesecu u usporedbi s risedronatom (svi p<0,03).
English: The incidence of delayed hip fracture healing was comparable between Aclasta (34 [3.2%]) and placebo (29 [2.7%]).
Croatian: Incidencija odgođenog zarastanja prijeloma kuka bila je usporediva za Aclastu (34 [3,2%]) i placebo
English: Rare cases of renal failure requiring dialysis and rare cases with a fatal outcome have been reported in patients with pre-existing renal dysfunction or other risk factors such as advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, or dehydration in the post infusion period (see sections 4.4 and 4.8 Class effects)
Croatian: Prijavljeni su rijetki slučajevi zatajenja bubrega koji zahtijevaju dijalizu i rijetki slučajevi sa smrtnim ishodom u bolesnika s već postojećom disfunkcijom bubrega ili drugim rizičnim faktorima poput poodmakle dobi, istodobnu primjenu nefrotoksičnih lijekova, istodobnu primjenu diuretske terapije, ili dehidraciju u razdoblju nakon infuzije (vidjeti dijelove 4.4 i 4.8 učinci po skupinama)
English: Aclasta was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Croatian: Aclasta je ispitivana u muških i ženskih bolesnika u dobi iznad 30 godina i u kojih je radiološki potvrđena primarno blaga do umjerena Pagetova bolest kosti (u vrijeme ulaska u kliničko ispitivanje medijan razine alkalne fosfataze u serumu bio je 2,6-3,0 puta veći od gornje granice normalnog referentnog raspona specifičnog za tu dob).
English: Aclasta is administered via a vented infusion line and given slowly at a constant infusion rate.
Croatian: Aclasta se primjenjuje polako putem infuzijske cjevčice s odzračivačem uz konstantnu brzinu infuzije.
English: • Patient reminder card on osteonecrosis of the jaw
Croatian: • Karticu s podsjetnikom za bolesnika o osteonekrozi čeljusti
English: In the HORIZON-RFT study Aclasta treatment significantly increased BMD at the total hip and femoral neck relative to treatment with placebo at all timepoints.
Croatian: U ispitivanju HORIZON-RFT liječenje Aclastom je značajno povećalo BMD cijelog kuka i vrata bedrene kosti obzirom na placebo u svim vremenskim točkama.
English: Zoledronic acid infusion resulted in an increase in the lumbar spine BMD Z-score least square (LS) mean difference of 0.41 at month 12 relative to baseline compared to placebo (95% CI: 0.02, 0.81;
Croatian: Infuzija zoledronatne kiseline rezultirala je povišenjem razlike srednje vrijednosti dobivene metodom najmanjih kvadrata za BMD Z-vrijednost u 12. mjesecu za 0,41 u odnosu na početnu vrijednost, u usporedbi s placebom (95% CI: 0,02, 0,81; 18 odnosno 16 bolesnika).
English: † Identified in post-marketing experience.
Croatian: † Utvrđeno u sklopu iskustava nakon stavljanja lijeka u promet.
English: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis.
Croatian: Atipični subtrohanterni i dijafizalni prijelomi bedrene kosti prijavljeni su s terapijom bisfosfonatima, prvenstveno u bolesnika koji se dugotrajno liječe od osteoporoze.
English: Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, including zoledronic acid (see section 4.4).
Croatian: Prijavljeni su slučajevi osteonekroze čeljusti pretežno u bolesnika s rakom liječenih lijekovima koji inhibiraju resorpciju kosti, uključujući zoledronatnu kiselinu (vidjeti dio 4.4).
English: Patients were randomised to either Aclasta 5 mg single infusion or to oral risedronate 5 mg daily for one year.
Croatian: Bolesnici su bili randomizirani ili za jednokratnu infuziju Aclaste u dozi od 5 mg, ili za peroralnu primjenu risedronata u dozi od 5 mg dnevno tijekom jedne godine.
English: Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
Croatian: Rijetko se mogu javiti neubičajeni prijelomi bedrene kosti, osobito u bolesnika na dugoročnoj terapiji za osteoporozu.
English: Placebo (N=1,062) event rate
Croatian: Placebo (n=1062) stopa događaja
English: In addition, in patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Aclasta administration (see section 4.2).
Croatian: Osim toga, u bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, najmanje tijekom 10 dana nakon primjene Aclaste (vidjeti dio 4.2).
English: The usual dose is 5 mg, given to you as one initial infusion into a vein by your doctor or nurse.
Croatian: Uobičajena doza je 5 mg, a daje Vam je liječnik ili medicinska sestra u obliku jednokratne infuzije u venu.
English: In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, Aclasta increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p<0.001).
Croatian: U subpopulaciji bolesnika koji su primali glukokortikosteroide 3 mjeseca ili kraće prije randomizacije, Aclasta je povećala BMD lumbalne kralježnice za 2,60% naspram 0,64% za risedronat (srednja razlika 1,96%; p<0,001).
English: Placebo (N=3,861) event rate
Croatian: Placebo (n=3861) stopa događaja (%)
English: Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation.
Croatian: Mogući štetni učinci zoledronatne kiseline na plodnost roditelja i F1 generaciju procjenjivali su se u štakora.
English: Renal impairment has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal dysfunction or additional risk factors (e.g advanced age, oncology patients with chemotherapy, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, severe dehydration), with the majority of them receiving a 4 mg dose every 3-4 weeks, but it has been observed in patients after a single administration.
Croatian: Oštećenje bubrega je zapaženo nakon primjene zoledronatne kiseline, osobito u bolesnika s već postojećom disfunkcijom bubrega ili dodatnim rizičnim faktorima (npr. poodmakla dob, onkološki bolesnici na kemoterapiji, istodobna primjena nefrotoksičnih lijekova, istodobna diuretska terapija, teška dehidracija), od kojih je većina primala dozu od 4 mg svaka 3-4 tjedna, no zapaženo je i u bolesnika nakon jednokratne primjene.
English: Bone biopsies were obtained from the iliac crest 1 year after the third annual dose in 152 post-menopausal patients with osteoporosis treated with Aclasta (N=82) or placebo (N=70).
Croatian: Biopsije kosti uzete su iz grebena ilijačne kosti 152 bolesnice u postmenopauzi s osteoporozom, liječene Aclastom (n=82) ili placebom (n=70), 1 godinu nakon treće godišnje doze.
English: Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.
Croatian: U tijeku evaluacije bolesnika u kojih se sumnja da imaju atipičan prijelom bedrene kosti treba razmotriti prekid terapije bisfosfonatima na temelju individualne procjene koristi i rizika.
English: In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, Aclasta increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p<0.001).
Croatian: U subpopulaciji bolesnika koji su primali glukokortikosteroide dulje od 3 mjeseca prije randomizacije, Aclasta je povećala BMD lumbalne kralježnice za 4,06% naspram 2,71% za risedronat (srednja vrijednost razlike: 1,36%; p<0,001).
English: Absolute reduction in fracture event rate
Croatian: Apsolutno smanjenje incidencije prijeloma
English: In patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Aclasta administration (see section 4.4).
Croatian: U bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija, koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, tijekom najmanje 10 dana nakon primjene Aclaste (vidjeti dio 4.4).
English: Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy
Croatian: Klinička djelotvornost u osteoporozi povezanoj s dugotrajnom sistemskom terapijom glukokortikosteroidima
English: Severe and occasionally incapacitating bone, joint and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including zoledronic acid (see section 4.8).
Croatian: Povremeno su prijavljeni teški, a ponekad i onesposobljavajući bolovi u kostima, zglobovima i/ili mišićima kod bolesnika koji uzimaju bisfosfonate, uključujući zoledronatnu kiselinu (vidjeti dio 4.8).
English: How to store Aclasta
Croatian: Kako čuvati Aclastu
English: Treatment with Aclasta resulted in a 6.7% increase in BMD at the lumbar spine, 6.0% at the total hip, 5.1% at the femoral neck, and 3.2% at the distal radius over 3 years as compared to placebo.
Croatian: Liječenje Aclastom dovelo je do 6,7%-tnog povećanja BMD-a lumbalne kralježnice, 6,0%-tnog porasta ukupne vrijednosti za kuk, 5,1%-tnog za vrat bedrene kosti i 3,2%-tnog porasta za distalni dio palčane kosti tijekom 3 godine, u usporedbi s placebom.
English: Aclasta 5 mg solution for infusion
Croatian: Aclasta 5 mg otopina za infuziju
English: Not known (frequency cannot be estimated from the available data) Pain in the mouth and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth; these could be signs of bone damage in the jaw (osteonecrosis).
Croatian: Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka) Bol u ustima i/ili čeljusti, oticanje ili ranice u ustima ili čeljusti koje ne cijele, iscjedak, utrnulost ili osjećaj težine u čeljusti, klimanje zuba.
English: No new vertebral fractures were observed in the zoledronic acid group as compared to two new fractures in the placebo group.
Croatian: U skupini koja je primala zoledronatnu kiselinu nisu zapaženi novi vertebralni prijelomi, dok su u skupini koja je primala placebo zabilježena dva nova prijeloma.
English: The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the first, second and third infusion, respectively.
Croatian: Ukupan postotak bolesnika koji su imali nuspojave nakon prve, druge, odnosno treće infuzije bio je 44,7%, 16,7% i 10,2%.
English: Aclasta must not be allowed to come into contact with any calcium-containing solutions.
Croatian: Aclasta ne smije doći u kontakt s otopinama koje sadrže kalcij.
English: In patients with a recent low-trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first Aclasta infusion.
Croatian: U bolesnika s nedavnim prijelomom kuka nakon manje traume, preporučuje se prije prve infuzije Aclaste dati udarnu dozu od 50 000 do 125 000 IU vitamina
English: Atrial fibrillation Uncommon Palpitations
Croatian: Atrijska fibrilacija Manje često Palpitacije
English: The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse.
Croatian: Uobičajena doza je 5 mg koju će Vam dati liječnik ili medicinska sestra u obliku jedne infuzije u venu jednom godišnje.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml vial of Aclasta, i.e., essentially “sodium free”.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po bočici Aclaste od 100 ml, tj. zanemarive količine natrija.
English: Aclasta is contraindicated during breast-feeding (see section 4.3).
Croatian: Aclasta je kontraindicirana tijekom dojenja (vidjeti dio 4.3).
English: (CI)
Croatian: A.
English: Renal impairment has been observed following the administration of Aclasta (see section 4.8), especially in patients with pre-existing renal dysfunction or other risks including advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy (see section 4.5), or dehydration occurring after Aclasta administration.
Croatian: Nakon primjene Aclaste bilo je zapaženo oštećenje bubrega (vidjeti dio 4.8), osobito u bolesnika s već postojećom disfunkcijom bubrega ili drugim rizicima uključujući poodmaklu dob, istodobnu primjenu nefrotoksičnih lijekova, istodobnu diuretsku terapiju (vidjeti dio 4.5), ili dehidraciju koja se pojavljuje nakon primjene Aclaste.
English: All participants received 1,000 mg elemental calcium plus 400 to 1,000 IU vitamin D supplementation per day.
Croatian: Svi sudionici su primili 1000 mg elementarnog kalcija plus 400 do 1000 IU nadomjestka vitamina
English: A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Aclasta in patients with concomitant risk factors.
Croatian: Prije početka liječenja Aclastom, u bolesnika s istodobnim rizičnim faktorima, preporučuje se stomatološki pregled uz obavljanje preventivnih stomatoloških zahvata i procjena individualne koristi i rizika.
English: Ocular hyperaemia
Croatian: Hiperemija oka
English: Cases of ONJ have been reported in the post-marketing setting for Aclasta.
Croatian: Prijavljeni su slučajevi ONJ za Aclastu nakon stavljanja lijeka u promet.
English: Uncommon Neck pain, musculoskeletal stiffness, joint swelling, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, joint stiffness, arthritis, muscular weakness
Croatian: Manje često Bol u vratu, mišićno-koštana ukočenost, oticanje zgloba, spazmi mišića, mišićno-koštana bol u prsištu, mišićno-koštana bol, ukočenost zgloba, artritis, slabost mišića
English: • Creatinine clearance should be calculated based on actual body weight using the
Croatian: • Prije svake doze Aclaste treba izračunati klirens kreatinina na temelju stvarne tjelesne težine koristeći Cockcroft-Gaultovu formulu.
English: PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING
Croatian: PODACI KOJI SE MORAJU NALAZITI NA SREDNJEM PAKIRANJU
English: No dose adjustment is necessary in patients with creatinine clearance ≥ 35 ml/min.
Croatian: U bolesnika s klirensom kreatinina ≥35 ml/min nije potrebna prilagodba doze.
English: Osteonecrosis of the jaw (ONJ)
Croatian: Osteonekroza čeljusti (ONJ)
English: Effect on hip fractures
Croatian: Učinak na prijelome kuka
English: The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth.
Croatian: U bolesnika sa nezacijeljenim otvorenim lezijama mekih tkiva u ustima treba odgoditi početak liječenja ili novi ciklus liječenja.
English: Talk to your doctor before you are given Aclasta: - if you are being treated with any medicine containing zoledronic acid, which is also the active substance of Aclasta (zoledronic acid is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium).
Croatian: Obratite se svom liječniku prije nego što primite Aclastu: - ako se liječite bilo kojim lijekom koji sadrži zoledronatnu kiselinu, koja je također djelatna tvar u Aclasti (zoledronatna kiselina se koristi u odraslih bolesnika s određenim tipovima raka kako bi se spriječile komplikacije s kostima ili smanjenje udjela kalcija). - ako imate probleme s bubrezima, ili ste ih ranije imali. - ako ne možete svaki dan uzimati nadomjestke kalcija. - ako Vam je iz vrata kirurški uklonjen dio ili sve paratireoidne žlijezde. - ako su Vam uklonjeni dijelovi crijeva.
English: Nervous system disorders
Croatian: Poremećaji imunološkog sustava
English: - Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. - The unopened bottle does not require any special storage conditions.
Croatian: - Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake „Rok valjanosti“.
English: Uncommon Conjunctivitis, eye pain Rare
Croatian: Manje često Konjunktivitis, bol u oku Rijetko
English: What Aclasta looks like and contents of the pack Aclasta is a clear and colourless solution.
Croatian: Aclasta je bistra i bezbojna otopina.
English: Your doctor should do a blood test to check your kidney function (levels of creatinine) before each dose of Aclasta.
Croatian: Prije svake doze Aclaste liječnik Vam mora napraviti krvnu pretragu kako bi provjerio Vašu bubrežnu funkciju (razine kreatinina).
English: Measurement of serum calcium before infusion of Aclasta is recommended for patients with Paget´s disease.
Croatian: Kod bolesnika s Pagetovom bolešću preporučuje se određivanje kalcija u serumu prije infuzije Aclaste.
English: Renal impairment has been observed in patients after a single administration.
Croatian: Oštećenje bubrega zabilježeno je u bolesnika nakon jednokratne primjene.
English: All women received 1,000 to 1,500 mg elemental calcium and 400 to 1,200 IU of vitamin D supplements daily.
Croatian: Sve su žene primale 1000-1500 mg elementarnog kalcija, uz nadomjestke prehrani s 400-1200 IU vitamina
English: Relative risk reduction in fracture incidence % (CI)
Croatian: Smanjene relativnog rizika u incidenciji prijeloma % (CI)
English: Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving Aclasta for the treatment of postmenopausal osteoporosis.
Croatian: Nepravilni otkucaji srca (treperenje pretklijetki) zabilježeni su u bolesnica koje su primale Aclastu zbog postmenopauzalne osteoporoze.
English: ONJ has been reported in the post-marketing setting in patients receiving Aclasta (zoledronic acid) for osteoporosis (see section 4.8).
Croatian: U bolesnika koji su primali Aclastu (zoledronatna kiselina) za osteoporozu prijavljena je ONJ nakon stavljanja lijeka u promet (vidjeti dio 4.8).
English: In the pooled results, a similar decrease in pain severity and pain interference scores relative to baseline were observed over 6 months for Aclasta and risedronate.
Croatian: Kada su rezultati bili objedinjeni, nakon 6 mjeseci zapaženo je slično sniženje u težini boli i zbrojeva interferencije boli u odnosu na početne vrijednosti za Aclastu i risedronat.
English: Not known** Renal impairment.
Croatian: Nepoznato** Oštećenje bubrega.
English: Effect on all clinical fractures The incidence rates of key clinical fracture variables are presented in Table 4.
Croatian: Stope incidencije ključnih varijabli kliničkih prijeloma prikazane su u Tablici 4. Tablica 4 Usporedbe incidencije ključnih varijabli kliničkog prijeloma između liječenja Ishod
English: Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture.
Croatian: Prijelomi su često obostrani, stoga je u bolesnika liječenih bisfosfonatima s prijelomom trupa bedrene kosti potrebno pregledati i bedrenu kost na suprotnoj nozi.